Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for ...
PROVECTUS BIOPHARMS (PVCT)
NASDAQ:AMEX Investor Relations:
provectusbio.com/financial-overview
Company Research
Source: Yahoo! Finance
the “Company”) (OTCQB: PVCT) today announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the University of Calgary's Cumming School of Medicine in Human Vaccines & Immunotherapeutics . Their paper demonstrates that PV-10, a formulation of the Company's proprietary, pharmaceutical-grade active pharmaceutical ingredient rose bengal sodium, activates the body's natural STING (stimulator of interferon genes) immune pathway, leading to stronger antigen presentation and more robust T-cell responses. The article, titled “ PV-10 as New Adjuvant Enhances Immune Responses in Hepatitis B Vaccination Through STING Pathway ,” is available here This novel STING-pathway mechanism suggests that PV-10 could potentially represent a safer, more efficacious, and differentiated alternative to widely used vaccine adjuvants such as aluminum salts, emulsions, saponins, and nucleic acid–based fragments, many of which face questions around safety, reactog
Show less
Read more
Impact Snapshot
Event Time:
PVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVCT alerts
High impacting PROVECTUS BIOPHARMS news events
Weekly update
A roundup of the hottest topics
PVCT
News
- Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine EfficacyGlobeNewswire
- Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder CancerGlobeNewswire
PVCT
Sec Filings
- 12/1/25 - Form SCHEDULE
- 11/28/25 - Form 4
- 11/21/25 - Form 4
- PVCT's page on the SEC website